Diabetes Drugs Ref
Diabetes Drugs Ref generates an estimated $0/month in revenue from 0 downloads/month on the App Store, according to AppCurrents estimates (updated 2026-06-18).
| Est. revenue / month | $0 |
|---|---|
| Est. downloads / month | 0 |
| Estimate confidence | low |
| Pricing | Free + IAP |
| Rating | 0.00 ★ (0 ratings) |
| Category | Medical |
| Released | 01.04.2026 |
| App last updated | 11.05.2026 |
| Platform | iOS |
Modeled monthly estimate · rating velocity · low confidence
About
Diabetes Drugs Reference — evidence-based pharmacology reference for diabetes drug classes. Based on NICE NG28 2022, ADA Standards of Care 2024, and SIGN 154. FREE — no purchase needed: — SGLT2 Inhibitors: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin with doses, CV outcomes and renal thresholds FULL ACCESS — £14.99/year unlocks: — GLP-1 Receptor Agonists: semaglutide, liraglutide, du…
Trends & analysis
Chart rank trend
US · overallWhy it's surfacing
Scout 29Ratings & velocity
Geographic reach
best rank · 0 storefrontsRevenue & downloads trend
monthly estimateIn-app purchases
1 tiersUpdate history
1 update tracked- v1.0.11mo ago
Version 1.0.1: SGLT2 Inhibitors now permanently free. Full access to all 9 drug classes, CV outcomes trials, prescribing guide, sick day rules and special situations via annual subscription — £14.99/year.
Diabetes Drugs Ref — FAQ
How many downloads does Diabetes Drugs Ref get?
Diabetes Drugs Ref sees an estimated 0 downloads per month on the App Store, per AppCurrents modeling.
Is Diabetes Drugs Ref free?
Diabetes Drugs Ref is free to download on the App Store, monetizing through in-app purchases.
When was Diabetes Drugs Ref released?
Diabetes Drugs Ref launched on the App Store on 01.04.2026. Its latest version shipped 11.05.2026.
